

AdaptVac wins EY Entrepreneur Of The Year 2021 in category Life Sciences, Denmark

Copenhagen, Denmark, March 25, 2022 – AdaptVac, announces winning the EY Entrepreneur Of The Year 2021 in the Life Sciences category for Denmark. The jury particularly emphasized the company's use of innovative technology, which opens up more opportunities in the future, as well as AdaptVac's efforts towards development of the Danish COVID-19 vaccine.

"The jury was impressed by the exciting and innovative technologies that AdaptVac uses in its work with vaccines. They use so-called platform technology, which provides a wide range of opportunities for the development of new vaccines and therapies against infectious diseases, cancer and immunological disorders.", says Rasmus Bloch Jespersen, associate partner in EY and responsible for Life Sciences-category.

The award comes on the heels of positive results from the Bavarian Nordic Phase II COVID-19 vaccine trial. Bavarian Nordic is currently preparing for a Phase III trial of ABNCoV2, expected to be initiated in the first half of 2022. Moreover, ExpreS²ion Biotechnologies has recently presented positive animal proof-of-concept data for the HER2 positive cancer cVLP vaccine licensed from AdaptVac.

"It is a great honor to receive the EY Entrepreneur Of The Year 2021 in the Life Sciences category for Denmark. This award further celebrates the potential of cVLP vaccine platform technology, as well as the incredible work by AdaptVac's employees and partners in the PREVENT-nCOV EU funded COVID-19 vaccine project. These efforts came during a particularly challenging time and demonstrates their dedication to fighting the pandemic. I especially want to thank our grant funders and collaborators from Copenhagen University, ExpreS²ion Biotechnologies, Radboud University Medical Centre, Århus University, AGC Biologics and Bavarian Nordic.", said Wian de Jongh, AdaptVac's CEO.

Additional information can be found in the press release published today by EY, see link https://www.ey.com/da_dk/news/2022/03/danske-vaccinemagere-vinder-pris-i-vaekstkonkurrence.

For further information about AdaptVac ApS, please contact:

Dr. Wian de Jongh, CEO

Telephone: +45 26394649

E-mail: wdj@adaptvac.com

Grant funding

The Prevent-nCOV consortium is funded by an EU Horizon 2020 grant to develop a COVID-19 vaccine (Grant agreement 101003608 <https://cordis.europa.eu/project/id/101003608>). Further the vaccine development at University of Copenhagen is supported by the Carlsberg Foundation, the Danish research councils and Gudbjørg og Ejnar Honorés Fond.

About AdaptVac

AdaptVac is a joint venture between ExpreS²ion Biotechnologies and NextGen Vaccines, owned by the inventors of the novel proprietary and ground-breaking viral capsid-like virus particle (cVLP) platform technology spun out from the University of Copenhagen. The Company aims to accelerate the development of highly efficient therapeutic and prophylactic vaccines within high value segments of oncology, infectious diseases and immunological disorders. Granting of the core patent in the U.S. has expanded AdaptVac's patent protection to include our entire pipeline of vaccines and immunotherapies in development. Please visit: www.AdaptVac.com

This press release was submitted for publication through the agency of the contact person set out above on March 25, 2022.